培美曲塞联合DC-CIK细胞维持治疗中晚期非小细胞肺癌的疗效观察

目的:比较培美曲塞联合树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)生物免疫治疗和单用培美曲塞在中晚期非小细胞肺癌(NSCLC)维持治疗中的疗效。方法:收集46例Ⅲ、Ⅳ期的中晚期NSCLC肺腺癌患者,均经过4个周期的含铂两药标准一线化疗,且得到有效控制。患者随机分为2组:对照组(23例)仅给予培美曲塞治疗,联合组(23例)采用培美曲塞联合DC-CIK治疗,比较2组临床疗效与不良反应发生情况。结果:2组患者疾病控制率分别为87.0%和78.3%,差异无统计学意义(P>0.05);联合组患者中位无进展生存期为6.9个月,优于对照组的4.7个月(P<0.01);2组患者的不良反应主要为骨髓抑制和胃肠道反应等,不良反应发生率差异均无统计学意义(P>0.05),联合组患者在DC-CIK回输过程中出现3例发热。结论:培美曲塞联合DC-CIK细胞维持治疗中晚期NSCLC是一种安全有效的方法。

Effect of the pemetrexed combined with DC-CIK cells in the treatment of moderate advanced non-small cell lung cancer

Objective:To compare the clinical effects between pemetrexed combined with dentritic cells( DC) ,cytokine induced killer cells(CIK),and pemetrexed in the treatment of moderate advanced non-small cell lung cancer(NSCLC). Methods:Forty-six patients with stage Ⅲ or Ⅳ NSCLC were treated with platinum-based two-drug chemotherapy for four cycles, the disease were effectively controlled,and the patients were randomly divided into the control group and combination group. The control group and combination group were treated with pemetrexed and pemetrexed combined with DC-CIK, respectively. The clinical efficacy and adverse reactions between two groups were compared. Results:The disease control rates in control group and combination group were 78. 3%and 87. 0%, respectively,the difference of which was not statistically significant(P >0. 05). The progression-free survival in combination group (6.9 months) was better than that in control group(4. 7 months)(P <0. 01). The bone marrow suppression and gastrointestinal reaction in two groups were the main adverse reactions,the difference of which was not statistically significant(P>0. 05). Fever in 3 cases were found in combination group during DC/CIK infusion. Conclusions:The maintenance treatment of NSCLC with pemetrexed combined with DC-CIK is a safe and effective method.